COMMUNIQUÉS West-GlobeNewswire

8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards.
06/11/2025
Ester Baiget, President & CEO: ” I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability and cash flow. Our performance was strong across all [...]
CARBIOS et Wankai New Materials, filiale du Groupe Zhink, s’engagent pour le déploiement à très grande échelle de la technologie de biorecyclage du PET de CARBIOS en Asie, avec comme première étape la construction d’une usine en Chine.
06/11/2025
Les deux Groupes se sont accordés de manière engageante sur les grands principes de leur collaboration, en vue de déployer une capacité de 1 million de tonnes à long terme, Débutant par la construction en Chine d’une [...]
CARBIOS and Wankai New Materials, a subsidiary of Zhink Group, are committed to the large-scale deployment of CARBIOS’ PET biorecycling technology in Asia, with the first step being the construction of a PET biorecycling plant in China.
06/11/2025
The two Groups have reached a binding agreement on the main principles of their collaboration, with a view to deploying a capacity of one million tonnes in the long term, Starting with the construction of a plant in [...]
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
06/11/2025
HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines [...]
BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of Bv100 in China
06/11/2025
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, Nov. 06, 2025 (GLOBE NEWSWIRE) -- First healthy volunteer dosed with BV100 in China in mandatory Phase 1 trial Inclusion of Chinese clinical sites by H2 [...]
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
06/11/2025
Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024 RUCONEST® third quarter revenu e increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting [...]
BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025
06/11/2025
SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it [...]
BillionToOne Announces Pricing of Upsized Initial Public Offering
06/11/2025
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced [...]
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
05/11/2025
Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficacy measures at Week [...]
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
05/11/2025
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/11/2025
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November 1, 2025, the [...]
Rhythm Pharmaceuticals annonce le remboursement public de l'IMCIVREE® (setmélanotide) au Canada dans cinq provinces et dans le cadre du Programme fédéral des services de santé non assurés
05/11/2025
IMCIVREE est désormais remboursé pour le cadre de la gestion du poids chez les patients atteints du syndrome de Bardet-Biedl (BBS) en Ontario, en Alberta, en Colombie-Britannique, en Saskatchewan, en Nouvelle-Écosse et [...]
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
05/11/2025
IMCIVREE now publicly covered for weight management due to Bardet-Biedl syndrome (BBS) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and under NIHB BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm [...]
HealthEquity Announces Third Quarter Earnings Date
05/11/2025
DRAPER, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest Health Savings Accounts (“HSA") and consumer-directed benefits administrator, [...]
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
05/11/2025
Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026 Company has initiated RASolute [...]
PacBio Announces Third Quarter 2025 Financial Results
05/11/2025
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025 Q3 2024 Revenue $38.4 million $40.0 [...]
Pennant Reports Third Quarter 2025 Results
05/11/2025
Conference Call and Webcast scheduled for tomorrow, November 6, 2025 at 10:00 am MT EAGLE, Idaho, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]
Senseonics Holdings, Inc. Reports Third Quarter Financial Results
05/11/2025
Generated Q3 revenue of $8.1 million, representing year-over-year growth of 90% Achieved a 160% increase in U.S. new patient starts over prior year Planning for the transition of CGM commercial responsibility from [...]
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
05/11/2025
SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]

Pages